← All trials
NCT06079359
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Jun 26, 2025
- Completion date
- Aug 26, 2027
- First posted
- Oct 12, 2023
- Last posted
- Dec 12, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AlexionLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.